Molecular Templates Announces Start of Phase 1 Clinical Trial of MT-3724 in Refractory Non-Hodgkin’s Lymphoma
Molecular Templates Presents Preclinical Data on CD38 Targeting Engineered Toxin Body (ETB) at AACR Special Conference
Molecular Templates Announces Completion of $12M Series C Financing
Molecular Templates Announces FDA Approval of Investigational New Drug Application for CD20 Internalizaing Immunotoxin MT-3724
There are currently no open positions at this time
©2014 Molecular Templates Inc.